Tamoxifen-Associated Hair Loss in Men

Incidence and Clinical Characteristics

Endocrine therapy-induced alopecia (EIA) from tamoxifen has been reported at rates up to 25% in meta-analysis data, though this may reflect reporting bias as younger patients may notice or report hair changes more readily 1, 2
The actual incidence is likely underreported in clinical trials and observational studies 1
EIA from tamoxifen typically presents as grade 1 alopecia (mild hair thinning) primarily affecting the crown of the scalp with recession of the frontal and bitemporal hairline 1, 2
Hair loss usually develops most prominently between 6 and 18 months after therapy initiation 1, 2

Tamoxifen-induced hair loss occurs through miniaturization of hair follicles and a decreased anagen-to-telogen ratio (fewer hairs in active growth phase, more in resting phase) 1, 2

When a man on tamoxifen presents with hair loss, rule out alternative causes through laboratory testing including thyroid function, iron stores, vitamin D, and zinc levels 1, 2
The American College of Physicians may recommend examining for male-pattern baldness, alopecia areata, or inflammatory scarring alopecia 1

For men with breast cancer, do not discontinue tamoxifen for hair loss alone, as the mortality benefit of tamoxifen in hormone receptor-positive male breast cancer far outweighs this cosmetic concern 3

The quality of life impact from mild hair thinning must be weighed against tamoxifen's proven survival benefit in male breast cancer, where it serves as the standard adjuvant therapy with a 62% relative risk reduction for ER-positive tumors 3